Zurcher Kantonalbank Zurich Cantonalbank grew its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) by 22.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,167 shares of the biotechnology company’s stock after purchasing an additional 2,804 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Aurinia Pharmaceuticals were worth $347,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Macquarie Group Ltd. purchased a new position in shares of Aurinia Pharmaceuticals in the third quarter worth $26,000. BNP Paribas Arbitrage SA purchased a new position in shares of Aurinia Pharmaceuticals in the third quarter worth $40,000. Geneos Wealth Management Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 717.1% in the third quarter. Geneos Wealth Management Inc. now owns 2,108 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,850 shares in the last quarter. Global Retirement Partners LLC purchased a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $99,000. Finally, Intrust Bank NA purchased a new position in shares of Aurinia Pharmaceuticals in the third quarter worth $208,000. Institutional investors and hedge funds own 33.90% of the company’s stock.
Several research firms have recently commented on AUPH. Royal Bank of Canada lowered their target price on shares of Aurinia Pharmaceuticals from $31.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday, March 1st. SVB Leerink reduced their target price on shares of Aurinia Pharmaceuticals from $30.00 to $22.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 8th. StockNews.com initiated coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, March 31st. They issued a “sell” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aurinia Pharmaceuticals in a report on Friday, April 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $33.00 target price (down from $40.00) on shares of Aurinia Pharmaceuticals in a report on Tuesday, March 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of “Buy” and an average target price of $27.20.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last posted its quarterly earnings results on Monday, February 28th. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. Aurinia Pharmaceuticals had a negative return on equity of 48.92% and a negative net margin of 396.81%. The business had revenue of $23.40 million for the quarter, compared to analyst estimates of $22.43 million. During the same quarter in the previous year, the firm earned ($0.05) EPS. As a group, equities research analysts expect that Aurinia Pharmaceuticals Inc. will post -0.67 earnings per share for the current fiscal year.
Aurinia Pharmaceuticals Company Profile (Get Rating)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
- Get a free copy of the StockNews.com research report on Aurinia Pharmaceuticals (AUPH)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.